美国 · SEC FORM 4
Merus N.V.
MRUS · — · CIK 0001651311 · Healthcare
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-12-29 · GENMAB A/S · $7.5B
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-29 · GENMAB A/S.
近期 Form 4 活动
11买入
2卖出
21其他 Form 4 交易行
10SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他0 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 76,920,005 | USD 97.00 | USD 7,461,240,485 | SEC 申报 ↗ |
| 2025-12-26 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 2,978 | USD 97.00 | USD 288,866 | SEC 申报 ↗ |
| 2025-12-26 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 142,610 | USD 97.00 | USD 13,833,170 | SEC 申报 ↗ |
| 2025-12-24 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 96,082 | USD 97.00 | USD 9,319,954 | SEC 申报 ↗ |
| 2025-12-23 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 561,042 | USD 97.00 | USD 54,421,074 | SEC 申报 ↗ |
| 2025-12-22 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 15,710 | USD 97.00 | USD 1,523,870 | SEC 申报 ↗ |
| 2025-12-19 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 66,264 | USD 97.00 | USD 6,427,608 | SEC 申报 ↗ |
| 2025-12-18 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 212,177 | USD 97.00 | USD 20,581,169 | SEC 申报 ↗ |
| 2025-12-17 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 150,795 | USD 97.00 | USD 14,627,115 | SEC 申报 ↗ |
| 2025-12-16 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 120,752 | USD 97.00 | USD 11,712,944 | SEC 申报 ↗ |
| 2022-11-03 | Lundberg Sven Ante | 买入 (P) | Common Shares | 14,706 | USD 14.38 | USD 211,472 | SEC 申报 ↗ |
| 2022-08-22 | Lundberg Sven Ante | 买入 (P) | Common Stock | 5,826 | USD 22.92 | USD 133,532 | SEC 申报 ↗ |
| 2022-08-19 | Lundberg Sven Ante | 买入 (P) | Common Stock | 704 | USD 22.99 | USD 16,185 | SEC 申报 ↗ |
| 2022-07-12 | Lundberg Sven Ante | 买入 (P) | Common Shares | 4,340 | USD 22.97 | USD 99,690 | SEC 申报 ↗ |
| 2021-03-30 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Shares, (euro)0.09 nominal value per share | 300,000 | USD 19.75 | USD 5,925,000 | SEC 申报 ↗ |
Form 4 申报证据
34 transaction lines in the latest 365-day window; 209 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 76,920,005 | USD 97.00 | USD 7,461,240,485 | SEC 申报 ↗ |
| 2025-12-26 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 2,978 | USD 97.00 | USD 288,866 | SEC 申报 ↗ |
| 2025-12-26 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 142,610 | USD 97.00 | USD 13,833,170 | SEC 申报 ↗ |
展开近期 Form 4 证据 (18 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 76,920,005 | USD 97.00 | USD 7,461,240,485 | SEC 申报 ↗ |
| 2025-12-26 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 2,978 | USD 97.00 | USD 288,866 | SEC 申报 ↗ |
| 2025-12-26 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 142,610 | USD 97.00 | USD 13,833,170 | SEC 申报 ↗ |
| 2025-12-24 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 96,082 | USD 97.00 | USD 9,319,954 | SEC 申报 ↗ |
| 2025-12-23 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 561,042 | USD 97.00 | USD 54,421,074 | SEC 申报 ↗ |
| 2025-12-22 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 15,710 | USD 97.00 | USD 1,523,870 | SEC 申报 ↗ |
| 2025-12-19 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 66,264 | USD 97.00 | USD 6,427,608 | SEC 申报 ↗ |
| 2025-12-18 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 212,177 | USD 97.00 | USD 20,581,169 | SEC 申报 ↗ |
| 2025-12-17 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 150,795 | USD 97.00 | USD 14,627,115 | SEC 申报 ↗ |
| 2025-12-16 | GENMAB A/S | 买入 (P) | Common Shares, nominal value EUR 0.09 per share | 120,752 | USD 97.00 | USD 11,712,944 | SEC 申报 ↗ |
| 2025-12-12 | Shuman Harry | U (U) | Common Shares | 11,002 | USD 97.00 | USD 1,067,194 | SEC 申报 ↗ |
| 2025-12-12 | Lundberg Sven Ante | U (U) | Common Shares | 65,052 | USD 97.00 | USD 6,310,044 | SEC 申报 ↗ |
| 2025-12-12 | Iwicki Mark T | U (U) | Common Shares | 73,576 | USD 97.00 | USD 7,136,872 | SEC 申报 ↗ |
| 2025-11-26 | Shuman Harry | 卖出 (S) | Common Shares | 1,700 | USD 96.10 | USD 163,370 | SEC 申报 ↗ |
| 2025-11-26 | Shuman Harry | 期权行权／转换 (M) | Common Shares | 1,700 | USD 21.69 | USD 36,875 | SEC 申报 ↗ |
| 2025-11-25 | Shuman Harry | 卖出 (S) | Common Shares | 8,300 | USD 95.92 | USD 796,136 | SEC 申报 ↗ |
| 2025-11-25 | Shuman Harry | 期权行权／转换 (M) | Common Shares | 7,300 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-25 | Lundberg Sven Ante | 赠与 (G) | Common Shares | 160,834 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | MRUS |
| CIK | 0001651311 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 209 transaction lines from 2020-01-02 to 2025-12-29 49 P purchase lines · 46 S sale lines · 114 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.